Walli A K, Seidel D
Res Exp Med (Berl). 1981;179(2):153-61. doi: 10.1007/BF01851983.
Administration of clofibric acid and bezafibrate to rats lowers plasma lipids, increases the liver weight, and causes a slight decrease in the activity of alkaline phosphatase in plasma. However, both these drugs increase the activity of alkaline phosphatase in liver over threefold. The activity of other enzymes did not change by the same magnitude. The increase in the alkaline phosphatase activity in liver tissue appears to be due to increase in the activity of this enzyme in parenchymal cells. Clofibric acid and bezafibrate increase the activity of bilirubin-glucuronyl transferase activity over twofold in liver microsomes. It is thus evident that both these drugs cause similar changes in various enzyme activities in liver even though bezafibrate has been reported to have a much shorter biologic halflife than clofibric acid.
给大鼠服用氯贝酸和苯扎贝特可降低血浆脂质、增加肝脏重量,并导致血浆碱性磷酸酶活性略有下降。然而,这两种药物均可使肝脏中碱性磷酸酶的活性增加三倍以上。其他酶的活性变化幅度不同。肝脏组织中碱性磷酸酶活性的增加似乎是由于实质细胞中该酶活性的增加。氯贝酸和苯扎贝特可使肝微粒体中胆红素葡糖醛酸基转移酶的活性增加两倍以上。因此很明显,这两种药物均可引起肝脏中各种酶活性的相似变化,尽管据报道苯扎贝特的生物半衰期比氯贝酸短得多。